Tevimbra Injection, Solution, Concentrate
Product Images NDC 72579-121

9 FDA label images from Beone Medicines Usa, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tevimbra (NDC 72579-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Beone Medicines Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tevimbra 01)

Figure 1 (Tevimbra 01)
A survival probability Kaplan-Meier curve comparing TEVIMBRA (tislelizumab-jsgr) to ICC over time in months. The graph shows overall survival probabilities on the y-axis and time in months on the x-axis, with TEVIMBRA represented by a solid line and ICC by a dashed line. Below the graph, a table lists the number of patients at risk for each group at various time points up to 32 months.*
FDA Label Image

Figure 2 (Tevimbra 02)

Figure 2 (Tevimbra 02)
Packaging label for TEVIMBRA (tislelizumab-jsgr) injection, 100 mg/10 mL (10 mg/mL) concentrate for intravenous infusion after dilution. The label indicates a 10 mL single-dose vial, with instructions to dispense with enclosed medication guide and discard unused portion. Manufactured by BeiGene USA, Inc., San Mateo, CA. Storage instruction specifies refrigeration at 2°C to 8°C (36°F to 46°F) and protection from light.*
FDA Label Image

Figure 3 (Tevimbra 03)

Figure 3 (Tevimbra 03)
A Kaplan-Meier survival curve comparing the survival probability (%) over time (months) between TEVIMBRA and ICC groups, with a table below showing the number of subjects at risk at different time points for both groups. TEVIMBRA is represented by circles and ICC by triangles on the plotted lines.*
FDA Label Image

Figure 4 (Tevimbra 04)

Figure 4 (Tevimbra 04)
A survival probability curve over time (months) comparing TEVIMBRA plus chemotherapy versus placebo plus chemotherapy. The graph includes survival percentages on the y-axis and time in months on the x-axis, with a table below showing the number of patients at risk for each treatment group at various time points.*
FDA Label Image

Figure 5 (Tevimbra 05)

Figure 5 (Tevimbra 05)
A Kaplan-Meier survival curve comparing survival probability (%) over time (months) between TEVIMBRA plus chemotherapy and placebo plus chemotherapy treatment groups. The graph includes the number of patients at risk at various time points for both groups.*
FDA Label Image

Figure 6 (Tevimbra 06)

Figure 6 (Tevimbra 06)
A survival curve graph showing overall survival (OS) probability percentage over time in months from randomization. The graph compares two treatment groups: Tras+Chemo (represented by triangles) and Zani+Tisle+Chemo (represented by circles), illustrating a higher survival probability for the latter group. The number at risk for each group is displayed below the time axis at various intervals.*
FDA Label Image

Figure 7 (Tevimbra 07)

Figure 7 (Tevimbra 07)
A Kaplan-Meier curve showing progression-free survival (PFS) probability (%) over time from randomization (months) comparing two treatment groups: Tras+Chemo and Zani+Tisle+Chemo. The X-axis represents months (0 to 45) and the Y-axis shows PFS probability from 0% to 100%. Number at risk data for each group is displayed below the X-axis.*
FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Principal Display Panel (10 mL Vial Carton)
Packaging label for TEVIMBRA (tislelizumab-jsgr) injection, concentrate, 100 mg/10 mL (10 mg/mL) for intravenous infusion after dilution. The label states it is a single-dose vial, to be dispensed with the enclosed medication guide, and includes storage instructions to refrigerate at 2°C to 8°C. Manufactured by BeOne Medicines USA, Inc. Product includes NDC 72579-121-01.*
FDA Label Image

Principal Display Panel (15 mL Vial Carton)

Principal Display Panel (15 mL Vial Carton)
Carton label for TEVIMBRA 150 mg/15 mL (10 mg/mL) injection, solution concentrate. The label shows tislelizumab-jsgr for intravenous infusion after dilution, dispensed with an enclosed medication guide. Manufactured by BeOne Medicines USA, Inc. The vial is single-dose and unused portions should be discarded.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.